CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for CanBas Co Ltd (Parent) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

CanBas Co Ltd (Parent)
2-2-1, Ote-machi
Phone: +81 559543666p:+81 559543666 NUMAZU-SHI, SZK  410-0801  Japan Ticker: 45754575
Business Summary
CanBas Co Ltd is a Japan-based company mainly engaged in pharmaceutical business. It is a drug discovery venture company engaged in basic research and clinical development of anticancer drugs. Its basic research on anticancer drugs includes examining drug discovery concepts, selecting drug candidate compounds using methods based on those concepts, simple animal testing, and collecting and analyzing basic data on anticancer drug candidate compounds that have already progressed to the development stage. It is engaged in early clinical development (preclinical trials and the first half of clinical trials conducted immediately before applying for clinical trial initiation) and late clinical development (the second half of clinical trials aimed at applying for new drug approval). Its development pipelines include CBP501, CBS9106, and follow-on pipelines such as CBT005, CBP-A08 and IDO/TDO inhibitor.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20256/30/2025Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Representative Director TakumiKawabe 54 5/1/2003 3/1/2001
Chief Financial Officer, Manager of Business Planning Office, Director MakotoKatozumi 59 10/1/2020 5/1/2009
Chief Operating Officer, Director of Research Development, Director ToshiyukiHibino 55 9/28/2021 10/1/2020
4 additional Officers and Directors records available in full report.

Business Names
Business Name
4575
CanBas Co Ltd
CanBas Co.,Ltd.

General Information
Number of Employees: 14 (As of 6/30/2025)
Outstanding Shares: 19,703,057 (As of 12/31/2025)
Shareholders: 13,689
Stock Exchange: TYO
Fax Number: +81 559543668


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, March 24, 2026